
    
      The purpose of this study is to identify the effect of prophylactic entecavir in HBsAg
      Negative/HBcAb Positive/hepatitis B virus DNA Negative patients with lymphoma are randomized
      into entecavir prophylaxis group or observation group. In entecavir prophylaxis group,
      entecavir 0.5 mg/day orally is initiate on day 1 of the first course of antitumor therapy,
      and will be continued until at least 6 months after completion of antitumor therapy. In
      observation group, entecavir 0.5mg daily will be prescribed for patients with hepatitis B
      virus reactivation.
    
  